SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Apple Turns 50: From Garage Startup to AI Crossroads 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
SOUTH SAN FRANCISCO, Calif., July 31, 2017 -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it will report its second quarter 2017 financial and operating results before the U.S. financial markets open on Monday, August 7, 2017. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:30 a.m. ET.
Conference Call and Webcast
To access the live conference call, please dial 844-494-0193 (domestic) or 508-637-5584 (international) and refer to the conference ID 62326435.
The webcast may be accessed live on the Investor Relations section of the Company’s website at http://investors.myokardia.com. A replay of the webcast will be available on the MyoKardia website for 90 days following the call.
About MyoKardia
MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardia’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM. MyoKardia’s most advanced product candidate is MYK-461. MYK-461 is a novel, oral, allosteric modulator of cardiac myosin that reduced hypercontractility in Phase 1 clinical studies of HCM patients. In April 2016, the U.S. FDA granted Orphan Drug Designation for MYK-461 for the treatment of symptomatic oHCM, a subset of HCM. MyoKardia is currently studying MYK-461 in PIONEER-HCM. MYK-491, the second clinical candidate generated by MyoKardia’s product engine, is designed to increase the overall extent of the heart’s contraction in DCM patients by increasing cardiac contractility. MyoKardia is currently evaluating MYK-491 in a Phase 1 study in healthy volunteers. A cornerstone of the MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry, or SHaRe, a multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia’s mission is to change the world for patients with serious cardiovascular disease through bold and innovative science. For more information, please visit www.myokardia.com.
Investor Contact: Beth DelGiacco Stern Investor Relations, Inc. 212-362-1200 [email protected] Media Contact: Steven Cooper Edelman 415-486-3264 [email protected]
